The Ozempic economy

The consumer experience is getting worse even as everything is getting more expensive. AI agents could make things better... or much, much worse. This episode was produced by Ariana Aspuru, edited by Jolie Myers, fact-checked by Gabriel Dunatov, engineered by David Tatasciore and ...  Show more

Texas hasn't elected a Democrat for Senate since 1988. James Talarico has a shot, but Republicans have launched a full culture war to try to prevent it. This episode was produced by Peter Balonon-Rosen, edited by Jolie Myers, fact-checked by Gabriel Dunatov, engineered by Bridger ...  Show more

Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ...  Show more

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Show more

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ...  Show more